the Master Plan on ASEAN Connectivity 2025, the ASEAN Outlook on the Indo-Pacific, the African Union’s Agenda 2063, and the European Union’s Strategy on Connecting Europe and Asia.
cic2025@mdpi.com Coatings 期刊介绍 主编:Emerson Coy, Adam Mickiewicz University in Poznań, Poland;Wei Pan, Tsinghua University, China 期刊专注于发表涂层、表面、界面及薄-厚膜领域的研究成果。目前,期刊已被 Scopus、ProQuest...
however, will only be possible with secured supplies. China has set a target for renewables to supply 33% of national power consumption by 2025. Renewable energy – mainly solar and wind
The Supreme Court on Tuesday stayed the Centre’s ban on Malayalam TV news channel Media One. The Central government had cited national security grounds to justify the ban. A bench headed by Justice D.Y. Chandrachud said the court is of the view that ground for providing interim relief is...
Main indicators including the change rate of fuel consumption, technology effectiveness, the change rate of technology effectiveness, and the fleet impact factor, are defined and indicated in Equations (1)–(6). For a certain year within the time frame (2015, 2020, 2025, 2030), we investigate...
Total citations (7.5%):This indicator measures how influential the university has been on the global research community. It is determined by multiplying the publications ranking factor by the normalized citation impact factor. Total citations have been normalized to overcome differences in research area...
Meet the experts in the upcoming Leading Conference at the 36th European Heart and Heart Failure Congress on July 24-25, 2025 at Paris, France
Cost per donation has a major impact on ROAS — the more it costs to generate a single gift, the more difficult it is to see a positive return. Search had a high ROAS, and we see a relatively low cost per donation of $55. Out of home has a low ROAS, and we see an actually ve...
专题投稿截止日期:2025年6月9日 复制下方链接至网页或识别二维码,进入专题主页。 https://www.mdpi.com/topics/VM4V8Q10TW 学术编辑团队 Prof. Dr. Andrzej Pacana 热索夫工业大学 研究领域:质量;环境管理;生产工程;ISO (国际标准化组织) 管理体系;物流;O...
access for people living with relapsing forms of multiple sclerosis,” Paul R. Lee, MD, PhD, director of the Division of Neurology II in the FDA Center for Drug Evaluation and Research, said in a statement.11“Today’s approval could have a meaningful impact for patients managing their ...